Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences Inc (FBRX) is a clinical-stage biopharmaceutical company developing FB-102, a novel therapeutic candidate targeting autoimmune conditions including graft-versus-host disease, vitiligo, and alopecia areata. This dedicated news hub provides real-time updates on preclinical advancements, regulatory milestones, and strategic initiatives shaping the company's research trajectory.
Access authoritative reports on key developments including trial design updates, intellectual property filings, and partnership announcements. Our curated news collection serves investors and researchers seeking to track FBRX's progress in immunomodulation therapies without promotional bias.
Content highlights include:
• Preclinical study results
• Research collaboration updates
• Financial performance reports
• Management commentary
Bookmark this page for streamlined access to verified FBRX developments. Regularly updated to reflect the company's evolving position in autoimmune therapeutics research.
Forte Biosciences, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced the issuance of equity inducement awards under Nasdaq rules.
The Compensation Committee approved grants for 70,000 shares to new non-executive employees to incentivize their employment. Each award will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly increments over the next three years.
The awards are part of Forte's 2020 Inducement Equity Incentive Plan and have terms similar to the 2021 Equity Incentive Plan.
Forte Biosciences, a clinical-stage biopharmaceutical firm, announced its Q1 2024 results. The company reported a net loss of $7.4 million, or $0.16 per share, an improvement from $0.32 per share in the same period last year. Forte's cash reserves stood at $30.4 million by the end of the quarter. R&D expenses dropped to $4.4 million from $4.8 million YoY, while G&A expenses rose to $3.5 million from $2.1 million. The company's phase 1 trial for its drug candidate FB102 has shown a good safety profile, with completion of multiple ascending dose cohorts expected mid-year. Forte plans to start patient-based studies by year-end, aiming to address various autoimmune diseases.
FAQ
What is the current stock price of Forte Biosciences (FBRX)?
What is the market cap of Forte Biosciences (FBRX)?
